Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers

Phase 1 Completed 34 enrolled Spero Therapeutics United States Department of Defense · collab

NaSingle-groupOpen-labelOther

Summary

To evaluate the intrapulmonary pharmacokinetics (PK), including epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations, of SPR206 as well as plasma concentrations of SPR206 in healthy adult volunteers.

Timeline

Start: 2021-06-03
Primary completion: 2021-09-16
Completion: 2021-09-29

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	UPLEGANAN	Other / unclassified	100 mg	Intravenous

Indications

No indication recorded.